KalVista Q1 2021 Earnings Report
Key Takeaways
KalVista Pharmaceuticals reported no revenue for the first fiscal quarter ended July 31, 2020, compared to $3.4 million for the same period in the prior fiscal year. Research and development expenses were $11.2 million, compared to $9.7 million for the same period in the prior fiscal year. Net loss was $10.8 million, or $(0.61) per share, compared to a net loss of $7.3 million, or $(0.42) per share, for the same period in the prior fiscal year.
KVD900 Phase 2 trial met enrollment target, with data expected in Q4 2020.
Completing formulation studies for KVD824, with pharmacokinetic and pharmacodynamic data expected later this year before starting a Phase 2 clinical trial.
Submitted a Pediatric Investigational Plan (PIP) to the European Medicines Agency (EMA) for KVD900.
Cash, cash equivalents and marketable securities were $64.3 million as of July 31, 2020, compared to $67.7 million as of April 30, 2020.